Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Red White & Bloom BrandsXCNQ:RWB Net Margin % is -91.77% as of Mar. 2026. The stock has 7 warning signs investors should review. Among 959 Drug Manufacturers companies, Red White & Bloom Brands ranks worse than 92.6% on this metric.
Red White & Bloom Brands (XCNQ:RWB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Red White & Bloom Brands Net Margin % Related Terms
Red White & Bloom Brands Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Red White & Bloom Brands's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Red White & Bloom Brands Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Red White & Bloom Brands's Net Margin % distribution charts can be found below:
* The bar in red indicates where Red White & Bloom Brands's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Red White & Bloom Brands (XCNQ:RWB) has a Net Margin % of -91.77% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Red White & Bloom Brands and its competitors. According to the industry distribution chart, Red White & Bloom Brands ranks #888 out of 959 companies in the Drug Manufacturers industry, placing it in the top 92.6%.
Is Red White & Bloom Brands' Net Margin % too high?
Red White & Bloom Brands' current Net Margin % is -91.77%. Based on the distribution chart, Red White & Bloom Brands ranks #888 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Red White & Bloom Brands' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Red White & Bloom Brands ranks #888 out of 959 companies for Net Margin %. This places Red White & Bloom Brands in the lower half of its industry. The industry median Net Margin % is 5.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.45, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Red White & Bloom Brands and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Red White & Bloom Brands's current Net Margin % is -91.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Red White & Bloom Brands stock overvalued right now?
Based on GuruFocus' analysis, Red White & Bloom Brands (XCNQ:RWB) is currently considered Modestly Undervalued. The stock's GF Value™ is C$0.04, compared to a current price of C$0.03 — trading 25% below its estimated fair value. The current Net Margin % is -91.77%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Red White & Bloom Brands (XCNQ:RWB), the current Net Margin % is -91.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Red White & Bloom Brands Inc is a multi-state operator in the United States conducting operations in the legal cannabis industry. The principal activity of the company is the sale of a diverse range of high-quality cannabis-based products delivered through its distribution and retail channels. The company operates twelve licensed adult-use and medical retail dispensaries located in the legal states of Michigan and Florida. The company operates in reportable segments: Corporate segment, Distribution segment, Licensing segment, Retail segment and Other. The key revenue is generated from Distribution segment. Geographically, the company operates in USA and Canada, where majority revenue is generated from USA.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XCNQ:RWB has been successfully added to your 
